A new muscle-building pill demonstrated promising results in an initial human trial, showing potential as an alternative to traditional exercise and fat-loss treatments. The study was conducted at the University of Copenhagen in Denmark and involved 13 overweight, sedentary men who took the daily tablet for eight weeks.

The pill, known as ATR-258, works by activating muscle receptors to enhance blood sugar absorption and stimulate the production of new muscle fibers. Participants in the trial lost an average of 1.1 kilograms (approximately 2 pounds 6 ounces) of fat while gaining around 800 grams (1 pound 12 ounces) of muscle. In addition, their leg strength improved by 13 percent over the course of the study.

Unlike some existing weight-loss medications such as Mounjaro, which can lead to muscle weakening, ATR-258 appeared to promote fat loss without compromising muscle mass. Study participants also reported no common side effects often associated with weight-loss drugs, such as muscle soreness or gastrointestinal discomfort.

Paul Little, CEO of Atrogi, the Swedish pharmaceutical company behind ATR-258, highlighted the potential impact of the findings. He noted that the muscle gain observed during the trial corresponds to the muscle strength typically lost over four to five years of aging. “The results look as good as the gym,” Little said, emphasizing that the improvements were achieved without requiring participants to alter their lifestyles or engage in exercise routines. Some participants even remarked that daily activities, such as carrying groceries up stairs, became noticeably easier.

Atrogi intends to build on these initial findings by conducting a larger-scale trial involving several hundred participants starting next year. The company suggested that combining ATR-258 with physical exercise might yield even greater benefits in muscle growth and overall fitness, although this remains to be tested in future studies.